Advertisement

Observation Versus Surgery for Nonlocalized Insulinoma

  • Anthony J. Chambers
  • Janice L. Pasieka
Chapter
Part of the Difficult Decisions in Surgery: An Evidence-Based Approach book series (DDSURGERY)

Abstract

Insulinoma are rare neuroendocrine tumors that almost always occur in the pancreas. They produce symptoms of episodic hypoglycemia secondary to the uncontrolled release of insulin. Using contemporary non-invasive and invasive investigations, insulinoma can be localized in as many as 97% of cases preoperatively. Insulinoma that cannot be localized preoperatively can be identified at the time of surgery with the aid of intraoperative ultrasound in more than 90% of cases and successfully removed. Surgery for insulinoma is associated with significant rates of morbidity (up to 68%), but a low mortality (0–5%). When surgery is not performed, long-term symptom control of hypoglycemia is achieved in only 55–78% of cases using medical management alone. Surgery is therefore recommended for the small percentage of insulinoma that are non-localized, and should be considered preferable to observation. The strength of this recommendation by GRADE criteria is assessed as weak. Given the paucity of evidence in the literature, the overall quality of the evidence supporting this recommendation is assessed as low by GRADE criteria. The investigation and management of patients with insulinoma should be performed at specialized institutions by experienced clinicians.

Keywords

Hyperinsulinism Insulinoma Neuroendocrine tumors 

References

  1. 1.
    Service FJ, McMahon MM, O’Brien PC, Ballard DJ. Functioning insulinoma – incidence recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991;66:711–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Hellman P, Goretski P, Dietmar S, Dotzenrath C, Roher HD. Therapeutic experience of 65 cases with organic hyperinsulinism. Langenbecks Arch Surg. 2000;385:329–36.CrossRefPubMedGoogle Scholar
  3. 3.
    Nikfarjam M, Warshaw AL, Axelrod L, Deshpande V, Thayer SP, Ferrone CR, et al. Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital. Ann Surg. 2008;247:165–72.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Tucker ON, Crotty PL, Conlon KC. The management of insulinoma. Br J Surg. 2006;93:264–75.CrossRefPubMedGoogle Scholar
  5. 5.
    Crippa S, Zerbi A, Boninsegna L, Capitanio V, Partelli S, Balzano G, et al. Surgical management of insulinoma: short and long-term outcomes after enucleations and pancreatic resections. Arch Surg. 2012;147:261–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Hirshberg B, Libutti SK, Alexander HR, Bartlett DL, Cochran C, Livi A, Chang R, Shawker T, et al. Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure. J Am Coll Surg. 2002;194:761–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Rothmund M, Angelini L, Brunt LM, Farndon JR, Geelhoed G, Grama D, et al. Surgery for benign insulinoma: an international review. World J Surg. 1990;14:393–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Bottger TC, Weber W, Beyer J, Junginger T. Value of tumor localization in patients with insulinoma. World J Surg. 1990;14:107–14.CrossRefPubMedGoogle Scholar
  9. 9.
    Rostambiegi N, Thompson GB. What should be done in an operating room when an insulinoma cannot be found? Clin Endocrinol. 2009;70:512–5.CrossRefGoogle Scholar
  10. 10.
    Noone TC, Hosey J, Firat Z, Semelka RC. Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab. 2005;19:195–211.CrossRefPubMedGoogle Scholar
  11. 11.
    Hamoud AK, Khan MF, Aboalmaali N, Usadel KH, Wullstein C, Vogl TJ. Mangan-enhanced MR imaging for the detection and localisation of small pancreatic insulinoma. Eur Radiol. 2004;14:923–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Krenning EP, Kwekkeboom DJ, Bakker WE, Breeman WA, Kooij PP, Oei HY, van Hagen M, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–31.CrossRefPubMedGoogle Scholar
  13. 13.
    van der Lely AJ, de Herder WW, Krenning EP, Kwekkeboom DJ. Octreoscan radioreceptor imaging. Endocrine. 2003;20:307–11.CrossRefPubMedGoogle Scholar
  14. 14.
    Sadowski SM, Neychev V, Cottle-Delisle C, Merkel R, Yang LA, Quezado MM, Chang R, Kebebew E. Detection of insulinoma using 68Gallium-DOTATATE PET/CT: a case report. Gland Surg. 2014;3:E1.PubMedPubMedCentralGoogle Scholar
  15. 15.
    McLean AM, Fairclough PD. Endoscopic ultrasound in the localisation of pancreatic islet cell tumours. Best Pract Res Clin Endocrinol Metab. 2005;19:177–93.CrossRefPubMedGoogle Scholar
  16. 16.
    Sotoudehmanesh R, Hedayat A, Shirazian N, Shahraeeni S, Ainechi S, Zeinali F, Kolahdoozan S. Endoscopic ultrasonography (EUS) in the localization of insulinoma. Endocrine. 2007;31:238–41.CrossRefPubMedGoogle Scholar
  17. 17.
    Gouya H, Vignaux O, Augui J, Dousset B, Palazzo L, Louvel A, Chaussade S, Legmann P. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. Am J Roentgenol. 2003;181:987–92.CrossRefGoogle Scholar
  18. 18.
    Abboud B, Boujaoude J. Occult sporadic insulinoma: localization and surgical strategy. World J Gastroenterol. 2008;14:657–65.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Lo CY, Chan FL, Tam SC, Cheng PW, Fan ST, Lam KS. Value of intra-arterial calcium stimulated venous sampling for regionalization of pancreatic insulinomas. Surgery. 2000;128:903–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Brändle M, Pfammatter T, Spinas GA, Lehmann R, Schmid C. Assessment of selective arterial calcium stimulation and hepatic venous sampling to localize insulin secreting tumours. Clin Endocrinol. 2001;55:357–62.CrossRefGoogle Scholar
  21. 21.
    Richards ML, Thompson GB, Farley DR, Kendrick ML, Service JF, Vella A, Grant CS. Setting the bar for laparoscopic resection of sporadic insulinoma. World J Surg. 2011;35:785–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Norton JA, Shawker TH, Doppman JL, Miller DL, Fraker DL, Cromack DT, Gorden P, Jensen RT. Localization and surgical treatment of occult insulinomas. Ann Surg. 1990;212:615–20.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Boukhman MP, Karam JM, Shaver J, Siperstein AE, DeLorimier AA, Clark OH. Localization of insulinomas. Arch Surg. 1999;134:818–23.CrossRefPubMedGoogle Scholar
  24. 24.
    Hashimoto LA, Walsh RM. Preoperative localization of insulinomas is not necessary. J Am Coll Surg. 1999;189:368–73.CrossRefPubMedGoogle Scholar
  25. 25.
    van Heerden JA, Grant CS, Czako PF, Charboneau JW. Occult functioning insulinomas: which localizing studies are indicated? Surgery. 1992;112:1010–4.PubMedGoogle Scholar
  26. 26.
    Hiramoto JS, Feldstein VA, LaBerge JM, Norton JA. Intraoperative ultrasound and preoperative localization detects all occult insulinomas. Arch Surg. 2001;136:1020–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Pasieka JL, McLeod MK, Thompson NW, Burney RE. Surgical approach to insulinomas: assessing the need for preoperative localization. Arch Surg. 1992;127:442–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Goode PN, Farndon JR, Anderson J, Johnston ID, Morte JA. Diazoxide in the management of patients with insulinoma. World J Surg. 1986;10:586–92.CrossRefPubMedGoogle Scholar
  29. 29.
    Gill GV, Rauf O, MacFarlane IA. Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J. 1997;73:640–1.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Stefanini P, Carboni M, Patrassi N, Bernardinis GD, Negro P. Problems of the management of insulinomas: review of 132 cases treated with medical measures. Acta Diabetol Lat. 1974;11:71–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Vezzosi D, Bennet A, Rochaix P, Courbon F, Selves J, Pradere B, Buscail L, et al. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol. 2005;152:757–67.CrossRefPubMedGoogle Scholar
  32. 32.
    Usukura M, Yoneda T, Yamamoto N, Takata H, Hasatani K, Takeda Y. Medical treatment of benign insulinoma using octreotide LAR: a case report. Endocr J. 2007;54:95–101.CrossRefPubMedGoogle Scholar
  33. 33.
    Kishikawa H, Okada Y, Hirose A, Tanikawa T, Kanda K, Tanaka Y. Successful treatment of insulinoma by a single daily dose of octreotide in two elderly female patients. Endocr J. 2006;53:79–85.CrossRefPubMedGoogle Scholar
  34. 34.
    Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med. 2009;360:195–7.CrossRefPubMedGoogle Scholar
  35. 35.
    de Herder WW, van Schaik E, Kwekkeboom D, Feelders RA. New therapeutic options for metastatic malignant insulinomas. Clin Endocrinol. 2011;75:277–84.CrossRefGoogle Scholar
  36. 36.
    Lo CY, Lam KY, Kung AW, Lam KS, Tung PH, Fan ST. Pancreatic insulinomas: a 15-year experience. Arch Surg. 1997;132:926–30.CrossRefPubMedGoogle Scholar
  37. 37.
    Ravi K, Britton BJ. Surgical approach to insulinomas: are pre-operative localization tests necessary? Ann R Coll Surg Engl. 2007;89:212–7.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, et al. GRADE guidelines: 1. Introduction – GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–94.CrossRefPubMedGoogle Scholar
  39. 39.
    Zhang T, Mu Y, Qu L, Wang X, Lv Z, Du J, Guo Q, Ba J, et al. Accurate combined preoperative localization of insulinomas aid the choice for enucleation: a single institution experience over 25 years. Hepatogastroenterol. 2012;59:1282–5.CrossRefGoogle Scholar
  40. 40.
    Varma V, Tariciotti L, Coldham C, Taniere P, Buckels JA, Bramhall SR. Preoperative localisation and surgical management of insulinoma: single centre experience. Dig Surg. 2010;28:63–73.CrossRefGoogle Scholar
  41. 41.
    Zhao YP, Zhang HX, Cong L, Dai MH, Liao Q, Cai LX. Surgical management of patients with insulinomas: results of 292 cases in a single institution. J Surg Oncol. 2011;103:169–74.CrossRefPubMedGoogle Scholar
  42. 42.
    Espana-Gomez MN, Velazquez-Fernandez D, Bezaury P, Sierra M, Pantoja JP, Herrera MF. Pancreatic insulinoma: a surgical experience. World J Surg. 2009;33:1966–70.CrossRefPubMedGoogle Scholar
  43. 43.
    Liu H, Peng C, Zhang S, Wu Y, Fang H, Sheng H, Peng S. Strategy for the surgical management of insulinomas: analysis of 52 cases. Dig Surg. 2007;24:463–70.CrossRefPubMedGoogle Scholar
  44. 44.
    Chung JC, Choi SH, Jo SH, Heo JS, Choi DW, Kim YI. Localization and surgical treatment of the pancreatic insulinomas. ANZ J Surg. 2006;76:1051–5.CrossRefPubMedGoogle Scholar
  45. 45.
    Chen X, Cai WY, Yang WP, Li HW. Pancreatic insulinomas: diagnosis and surgical treatment of 74 patients. Hepatobiliary Pancreat Dis Int. 2002;1:458–61.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Surgical OncologySt Vincent’s Hospital and University of New South WalesSydneyAustralia
  2. 2.Faculty of MedicineUniversity of Calgary and Tom Baker Cancer CentreCalgaryCanada

Personalised recommendations